Savara (SVRA) Stock Price & Analysis
Score
AI Analysis
SnapshotSavara is a growth-led story right now — Growth 100/100 is the pillar doing the heavy lifting (overall 67/100) in Biotechnology. In Biotechnology, that score mix is usable but not one-dimensional. Street targets still imply ~116% upside.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Savara Inc. (SVRA) last printed $4.64. Equity value is $1.02B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $400,000.00 | $0.00 | $0.00 | $0.00 | $257,000.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
About
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.